In 2022 the company made a revenue of N/A a decrease over the years 2021 revenue that were of $0.88 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | N/A | |
2022 | N/A | -100% |
2021 | $0.88 M | -77.61% |
2020 | $3.93 M | -89.11% |
2019 | $36.14 M | 649.51% |
2018 | $4.82 M | 97.62% |
2017 | $2.44 M | 27.66% |
2016 | $1.91 M | 194.8% |
2015 | $0.64 M | |
2014 | N/A |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Viking Therapeutics
VKTX | N/A | N/A | ๐บ๐ธ USA |
Vanda Pharmaceuticals VNDA | $0.19 B | N/A | ๐บ๐ธ USA |
Epizyme EPZM | $53 M | N/A | ๐บ๐ธ USA |
Advaxis ADXS | $0.11 M | N/A | ๐บ๐ธ USA |